On September 9, 2022, during the international conference of the European Society of Medical Oncology (ESMO), updates of two phase III clinical trials (PAOLA and SOLO-1) of olaparib conducted in patients with advanced ovarian cancer (FIGO III + FIGO IV) in first-line maintenance treatment were presented.
- For the first time, an increase in overall survival was shown for patients using olaparib after first-line chemotherapy, olaparib for patients with BRCA1/2 mutation and olaparib with bevacizumab for patients with BRCA1/2 and HRD mutations - says Dr. n. med. Anita Chudecka-Głaz, prof. PUM, head of the Department of Surgical Gynecology and Gynecological Oncology of Adults and Girls, SPSK 2 in Szczecin, provincial consultant in the field of oncological gynecology.
- The Proffered Paper session on the first day of ESMO 2022 presented the ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
